Pharmaceutical News and Articles

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

NEWARK, California, OSAKA, Japan and CAMBRIDGE, Massachusetts, March 3, 2025 Protagonist Therapeutics, Inc. ( Protagonist ) (NASDAQ PTGX) and Takeda (TSE 4502 N

Longtime NIH Leader Francis Collins Retires

Dr. Francis Collins, the famed geneticist who led the National Institutes of Health (NIH) for 12 years and helped guide the U.S. through the COVID pandemic, has

Duke Doctors Perform First Living Mitral Valve Transplant

In a groundbreaking series of surgeries, doctors at Duke Health have successfully performed the world s first living mitral valve replacement, saving the lives

Electric Vehicle Fires May Raise Cancer Risk for Communities

As electric vehicles (EVs) become more common on roads, they bring new health concerns for firefighters and the community, new research shows. Researchers at th

Psychosomatic Misdiagnosis Can Have Lasting Negative Impact on Patients

Chronic diseases misdiagnosed as psychosomatic can lead to long-term damage to patients physical and mental well-being, according to a study published online Ma

Sotagliflozin Cuts MACE Rate in Patients With T2DM, CKD, CVD Risk Factors

For patients with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk factors, the dual sodium-glucose co-transporter (SGLT)-1 2 inhibit

GLP-1 Receptor Agonist Use Not Linked to Increased Suicide Risk

Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) inhibit

Mortality Increased With Hospital-Based Care for Hallucinogen Use

Hospital-based care for hallucinogen use is associated with increased mortality, according to a study published online March 3 in CMAJ, the journal of the Canad

AAAAI: Omalizumab Superior to Oral Immunotherapy in Multifood Allergy

Omalizumab is superior to oral immunotherapy (OIT) for multifood allergy, and most patients include dietary consumption (DC) of allergy-triggering foods after g

Depemokimab Applications Accepted for Review by the US FDA for Asthma with Type 2 Inflammation and for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)